Iron in multiple myeloma

Critical Reviews in Oncogenesis

Volumn 18, Issue 5, 2013, Pages 449-461

  Vanderwall, Kristina ^a   Daniels Wells, Tracy R ^a   Penichet, Manuel ^a,b   Lichtenstein, Alan ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bone morphogenetic protein; Hepcidin; Interleukin 6; Multiple myeloma; Transferrin receptors

Indexed keywords

ANTIANEMIC AGENT; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN 9; DEFEROXAMINE; DI 2 PYRIDYLKETONE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; GALLIUM; HEMOGLOBIN; HEPCIDIN; IMMUNOMODULATING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; IRON; JANUS KINASE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PROTEIN MCL 1; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT INTERLEUKIN 6; SMAD PROTEIN; STAT PROTEIN; STAT3 PROTEIN; THIOSEMICARBAZONE DERIVATIVE; TRANSFERRIN; TRANSFERRIN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CELL PROLIFERATION; COST EFFECTIVENESS ANALYSIS; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; ERYTHROCYTE; ERYTHROPOIESIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; IRON CHELATION; IRON DEFICIENCY; IRON METABOLISM; IRON OVERLOAD; IRON TRANSPORT; KIDNEY FAILURE; LIVER CELL; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OVERALL SURVIVAL; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; QUALITY OF LIFE; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANEMIA; ANIMALS; HEPCIDINS; HUMANS; IRON; IRON CHELATING AGENTS; MULTIPLE MYELOMA; RECEPTORS, TRANSFERRIN;

EID: 84880631247     PISSN: 08939675     EISSN: 21626448     Source Type: Journal    
DOI: 10.1615/CritRevOncog.2013007934     Document Type: Article

References (73)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516-20.
3. Harrousseau JL, Moreau P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med. 2009;360:2645-54.
4. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N ENgl J Med. 2002;346:564-9.
5. Kyle RA, Gertz, M, Witzig T, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Pleval ME, Therneau TM, Greipp PR. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21-33.
6. Kyle RA. Multiple myeloma: Review of 869 cases. Mayo Clin Proc. 1975;50:29-40.
7. Musto P, Falcone A, D'Arena G. Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesis. Eur J Hematol. 1997;58:314-9.
8. Cella, D. The Functional Assessment of Cancer TherapyAnemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34: 13-9.
9. Caro J, Salas M, Ward A, Gross G. Anemia as an independent prognostic factor for survival in patients with cacner: a systemic, quantitative review. Cancer. 2001;91:2214-21.
10. Samson D. Guideline: diagnosis and management of multiple myeloma. Br J Haematol. 2001;155:522-40.
11. Kyle RA. Monoclonal Gammopathy of Undetermined Significance: Natural history in 241 cases. Amer J of Med. 1978;64:814-26.
12. Alexanian R. Localized and indolent myeloma. Blood. 1980;56:521-5.
13. Cremieux PY, Barrett B, Anderson K, Slavin MB. Cost of outpatient blood transfusion in cancer patients. J Clin Oncol. 2000;18:2755-61.
14. Mittelman, M. The implications of anemia in multiple myeloma. Clinical Lymphoma. 2003; 4:S23-S29.
15. Lippi G, Franchini M, Favaloro EJ.Thrombotic complications of erythropoiesis-stimulating agents. Sem Thromb Hemost. 2010;36:537-49.
16. Bennett CL, Silver SM, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Yarnold PR, Kuzel TM, Tallman MS, Trifilio SM, Lai Sy, Henke M. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914-24.
17. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelis S, Seidenfeld J, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Fey MF, Machtay M, Moebus V, Thomas G, Untch M, Egger M, Engert A. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomized trials. Lancet. 2009;373:1532-42.
18. Aapro MS, Birgegard G, Bokemeyer C, Cornes P, Foubert J, Gascon P, Glaspy J, Link H, Ludwig H, Osterborg A, Repetto L, Soubeyran P. Erythropoietins should be used according to guidelines. Lancet Oncology. 2008;9:412-3.
19. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Bennett CL, Goode MJ, Regan DH, Somerfield MR. American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer. Blood. 2010;116:4045-4059.
20. Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86:57-65.
21. Ludwig H, Pohl G, Osterborg A. Anemia in multiple myeloma. Clin Advan Hematol Oncol. 2004;2:233-41.
22. Beguin Y, Yerna M, Loo M, Weber M, Fillet G. Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Brit J of Hemat. 1992; 82:648-53.
23. Silvestris F, Cafforio P, Tucci M, Dammacco F. Negative regulation of erythroblast maturation by Fas-L(+)/ TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood. 2002; 99:1305-13.
24. Rivera S, Liu L, Nemeth E, Gabayan V, Sorensen OE, Ganz T. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood. 2005;105:1797-802.
25. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:20090-3.
26. Ganz T. Molecular pathogenesis of anemia of chronic disease. Pediatr Blood Cancer. 2006; 46:554-7.
27. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101:2461-13.
28. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J of Clin Invest. 2004;113:1271-6.
29. Klein B, Zhang XG, Jourdan M, Boiron JM, Portier M, Lu ZY, Brochier J, Bataille R. IL-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur Cytokine Netw. 1990;1:193-201.
30. Nachbaur DM, Herold M, manescheg A, Huber H. Serum levels of IL-6 in multiple myeloma and other disorders: correlation with disease activity and other prognostic parameters. Ann Hematol. 1991;62:54-8.
31. Sharma S, nemeth E, Chen Y-H, Goodnough J, Hustin A, Roodman GD, Ganz T, Lichtenstein A. Involvement of hepcidin in the anemia of multiple myeloma. Clin Canc Res. 2008;14:3262-67.
32. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood. 2006;108:3730-5.
33. Maes K, Nemeth E, Roodman GD, Huston A, Esteve F, Freytes C, Callander N, Katodritou E, TussingHumphreys L, Rivera S, Vanderkerken K, Lichtenstein A, Ganz T. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood. 2010;116:3635-44.
34. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008;112:4292-7.
35. Katodritou E, Ganz T, Terpos E, Verrou E, Olbina G, Varthaliti M, Westerman M, Zervas K. Sequential evaluation of serum hepcidin in anemic myeloma patients: study of correlations with myeloma treatment, disease variables and anemia response. Amer J Hemat. 2009; 84:524-6.
36. Lichtenstein A, Berenson J, Norman D, Chang MP, Carlile A. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma Blood. 1989;74:1266-73.
37. Donovan KA, LAcy MQ, Gerrtz MA, Lust JA. IL-1 beta expression in IgM MGUS and its relationship to multiple myeloma Leukemia. 2002;16:382-5.
38. Lee P, Peng H, Gelbart T, Wang L, Beutler E. Regulation of hepcidin transcription by IL-1 and IL-6. Proc Natl Acad Sci. 2005;102:1906-10.
39. Inamura J, Ikuta K, Jimbo J, Shindo M, Sato K,Torimoto Y, Kohgo Y. Upregulation of hepcidin by IL-1beta in human hepatoma cell lines. Hepatol Res. 2005;33:198-205.
40. Grcevic D, Kusec R, Kovacic N, Lukic A, Lukic IK, Nemet D, Ostojic SK, Croucher PI, Marusic A. Bone morphogenetic proteins and receptors are over-expressed in bone marrow cells of multiple myeloma patients and support myeloma cells by inducing ID genes. Oncogene. 2010;34:742-51.
41. Wrighting DM, Andrews NC. IL-6 induces hepcidin expression through STAT3. Blood. 2006;108:3204-9.
42. Truksa J, Lee P, Beutler E. Two BMP responsive ele ments, STAT and bZIP/HNF4/COUP motifs of the hepcidin promoter are critical for BMP, SMAD1 and HJV responsiveness. Blood. 2009;113:688-95.
43. Kovacevic Z, Kalinowski DS, Lovejoy DB, Yu Y, Suryo Rahmanto Y, Sharpe PC, Bernhardt PV, Richardson DR. The medicinal chemistry of novel iron chelators for the treatment of cancer. Curr Top Med Chem. 2011;11:483-99.
44. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol. 2006;121:144-58.
45. Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev. 2005;57:547-83.
46. Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A. 2006;103:14901-6.
47. Yuan J, Lovejoy DB, Richardson DR. Novel di-2-pyridylderived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood. 2004;104:1450-8.
48. Noulsri E, Richardson DR, Lerdwana S, Fucharoen S, Yamagishi T, Kalinowski DS, Pattanapanyasat K. Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells. Am J Hematol. 2009;84:170-6.
49. Chitambar CR. Medical applications and toxicities of gallium compounds. Int J Environ Res Public Health. 2010;7:2337-61.
50. Harris WR, Pecoraro VL. Thermodynamic binding constants for gallium transferrin. Biochemistry. 1983;22:292-9.
51. Warrell RP, Jr., Lovett D, Dilmanian FA, Schneider R, Heelan RT. Low dose gallium nitrate for prevention of osteolysis in myeloma: results of a pilot randomized study. J Clin Oncol. 1993;11:2443-50.
52. Niesvizky R. Gallium nitrate in multiple myeloma: prolonged survival in a cohort of patients with advanced-stage disease. Semin Oncol. 2003;30:20-4.
53. Eberhard Y, McDermott SP, Wang X, Gronda M, Venugopal A, Wood TE, Hurren R, Datti A, Batey RA, Wrana J, Dick JE, Schimmer AD. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood. 2009;114:3064-73.
54. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin down-regulates NF-kB in human multiple myeloma cells leading to suppression of proliferation and induction of apoptosis. Blood. 2003;101:1053-62.
55. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci. 2008;65:1631-52.
56. Jiao Y, Wilkinson Jt, Di X, Wang W, Hatcher H, Kock ND, D'Agostino R, Torti FM, Torti SV. Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood. 2009;113:462-9.
57. Qing Y, Shuo W, Zhihua W, Huifen Z, Ping L, Lijiang L, Liming C, Yu H, Wei X, Min F, Zuohua F, Guanxin S. The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor. Cancer Immunol Immunother. 2006;55:1111-21.
58. Daniels TR, Bernabeu E, Rodriguez JA, Patel S, Kozman M, Chiappetta DA, Holler E, Ljubimova JY, Heiguera G, Penichet ML. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta. 2012;1820:291-317.
59. Daniels TR, Delgado T, Helguera G, Penichet ML. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol. 2006;121:159-76.
60. Trowbridge IS, Lesley J, Schulte R. Murine cell surface transferrin receptor: studies with an anti-receptor monoclonal antibody. J Cell Physiol. 1982;112:403-10.
61. Gosselaar PH, van-Dijk AJ, de-Gast GC, Polito L, Bolognesi A, Vooijs WC, Verheul AF, Krouwer HG, Marx JJ. Transferrin toxin but not transferrin receptor immunotoxin is influenced by free transferrin and iron saturation. Eur J Clin Invest. 2002;32:61-9.
62. Taetle R, Castagnola J, Mendelsohn J. Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies. Cancer Res. 1986;46:1759-63.
63. Brooks D, Taylor C, Dos Santos B, Linden H, Houghton A, Hecht TT, Kornfeld S, Taettle R. Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6. Clin Cancer Res. 1995;1:1259-65.
64. Taetle R, Dos Santos B, Ohsugi Y, Koishihara Y, Yamada Y, Messner H, Dalton W. Effects of combined antigrowth factor receptor treatment on in vitro growth of multiple myeloma. J Natl Cancer Inst. 1994;86:450-5.
65. Ng PP, Dela Cruz JS, Sorour DN, Stinebaugh JM, Shin SU, Shin DS, Morrison SL, Penichet ML. An antitransferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proc Natl Acad Sci U S A. 2002;99:10706-11.
66. Ng PP, Helguera G, Daniels TR, Lomas SZ, Rodriguez JA, Schiller G, Bonavida B, Morrison SL, Penichet ML. Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood. 2006;108:2745-54.
67. Ortiz-Sanchez E, Daniels TR, Helguera G, MartinezMaza O, Bonavida B, Penichet ML. Enhanced cytotoxicity of an anti-transferrin receptor IgG3-avidin fusion protein in combination with gambogic acid against human malignant hematopoietic cells: functional relevance of iron, the receptor, and reactive oxygen species. Leukemia. 2009;23:59-70
68. Rodriguez JA, Luria-Perez R, Lopez-Valdes HE, Casero D, Daniels TR, Patel S, Avila D, Leuchter R, Bonavida B, Martinez-Maza O, Charles AC, Pellegrini M, Helguera G, Penichet ML. Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells. Leuk Lymphoma. 2011;52:2169-78.
69. Daniels TR, Ng PP, Delgado T, Lynch MR, Schiller G, Helguera G, Penichet ML. Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells. Mol Cancer Ther. 2007;6:2995-3008.
70. Daniels TR, Ortiz-Sanchez E, Luria-Perez R, Quintero R, Helguera G, Bonavida B, Martinez-Maza O, Penichet ML. An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies. J Immunother. 2011;34:500-8.
71. Gross S, Helm K, Gruntmeir JJ, Stillman WS, Pyatt DW, Irons RD. Characterization and phenotypic analysis of differentiating CD34+ human bone marrow cells in liquid culture. Eur J Haematol. 1997;59:318-26.
72. Knaan-Shanzer S, van der Velde-van Dijke I, van de Watering MJ, de Leeuw PJ, Valerio D, van Bekkum DW, de Vries AA. Phenotypic and functional reversal within the early human hematopoietic compartment. Stem Cells. 2008;26:3210-7.
73. Peschle C, Botta R, Muller R, Valtieri M, Ziegler BL. Purification and functional assay of pluripotent hematopoietic stem cells. Rev Clin Exp Hematol. 2001;5:3-14.